Pharmaceutical Research
Thalidomide shows no interaction with P-glycoprotein
Published in Clinical Oncology Week, April 10th, 2006
"There is growing clinical interest in thalidomide for the treatment of various disorders due to its anti-inflammatory, immunomodulatory, and antiangiogenic properties. In numerous clinical trials thalidomide is used as an adjunct to standard therapy," scientists in Switzerland report.
"Therefore, clinicians should be aware of all possible drug-drug interactions that might occur with this drug. P-gp, a drug efflux transporter that is expressed in many tissues, is the cause of several drug-drug interactions. P-gp induction or inhibition can lead to ineffective therapy or side-effects,"...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Clinical Oncology Week
More Articles from Clinical Oncology Week
- Bladder Cancer
Nonmuscle invasive micropapillary bladder carcinoma treated by early cystectomy - Lung Cancer
Lung cancer treated by irinotecan and cisplatin - Prostate Cancer
Prostate cancer diagnosed after repeat biopsies linked to favorable prognosis - Radiotherapy
Link between quality of life and fatigue in cancer patients receiving radiotherapy assessed - Soft Tissue Sarcomas
Soft tissue sarcoma should not be treated with gemcitabine as first-line chemotherapy - Acute Myeloid Leukemia
Acute myeloid leukemia outcome not improved after daunorubicin, cytarabine, and thioguanine therapy - More from this issue of Clinical Oncology Week
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
